Roche Diagnostics India announced the launch of its first Cobas 8800 instrument at National Institute of Cholera and Enteric Diseases, Kolkata also known as ICMR-NICED and Cobas 6800 at National Institute for Research in Reproductive Health, Mumbai also known as ICMR- NIRRH to aid with SARS CoV-2 diagnostic testing.
Operating on the real-time reverse transcription polymerase chain reaction (RT-PCR) platform, SARS-CoV-2 diagnostic tests on the instrument detects the genetic signature (RNA) of the virus in a simple test performed by a healthcare provider using nasopharyngeal and oropharyngeal swab samples.
The widely available Roche’s Cobas 6800/8800 systems provides test results in three and half hours and offer improved operating efficiency, flexibility and fastest time-to-time results.
Dr. Shravan Subramanyam, Managing Director India and Neighbouring markets, Roche Diagnostics India said, “Diagnostic testing is an important element of India’s battle against COVID-19, as we see a steady rise in infections across almost all parts of the country. High-volume and high-quality diagnostic tests are important to provide appropriate clinical support in time and implement social measures that can further avoid the infected spread the virus.”
He further added,”The cobas 6800/8800 addresses almost all of the challenges faced by the labs in pandemic times with reduced turnaround time, maintaining testing efficiency and improved productivity of lab personnel on account of automation.”
With the highest throughput providing up to 96 results in about three hours and a total of 384 results for the cobas 6800 System and 960 results for the cobas 8800 System in 8 hours. The test can be run simultaneously with other diagnostic assays provided by Roche Diagnostics, including HIV and Hepatitis.
- Diet & Nutrition plan for a Head and Neck Cancer Patient - January 17, 2022
- COVID-19: HC urged to direct govt to give road map to vaccinate kids of 12 yrs and below - January 17, 2022
- 2,500 Delhi Police personnel infected, 767 cured of Covid since January 1 - January 17, 2022
- AstraZeneca vaccine trials show 3 doses give good protection against Omicron: Serum CEO - January 13, 2022
- Omicron Alert: FFD Launches Free Helpline For Diabetics - January 13, 2022
- Alkem Laboratories to Launch State of the Art Technology for Diabetic Foot Ulcer Management - January 13, 2022
- Metropolis Healthcare launches the 3rd edition of MedEngage Scholarship program to support aspiring young medical students - January 12, 2022
- Infections could surge 6 times higher due to omicron: Russia - January 12, 2022
- Makar Sankranti: Odisha bans religious gatherings; no holy dip at Haridwar - January 12, 2022
- Indonesia starts COVID boosters for elderly - January 12, 2022